Loading stock data…
RYTM
$81.81+0.45 (+0.55%)
Market ClosedLast close May 1
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rhythm Pharmaceuticals, Inc. in the Healthcare sector is trading at $81.81. The stock is currently 33% below its 52-week high of $122.20, remaining 16.9% below its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why RYTM maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$81.81
Potential Upside
5%
Whystock Fair Value$85.90
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$137.67+68.3%
Range$105.00 – $158.00
Fundamentals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-67.81%
Volume
Today's trading volume
599,906
Recent News
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) ranks 5th on this list. While Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) faces high cash burn, hedge funds are piling into the stock due to its successful precision obesity pivot, which separates it from the broad-market GLP-1 (Ozempic/Wegovy) […]
Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now?
Is RYTM a good stock to buy? We came across a bearish thesis on Rhythm Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bears’ thesis on RYTM. Rhythm Pharmaceuticals, Inc.’s share was trading at $87.72 as of April 20th. Rhythm Pharmaceuticals (RYTM) is a rare-disease biotech built almost entirely around setmelanotide, an MC4R agonist targeting genetic […]
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments
Rhythm Pharmaceuticals now carries a Fair Value price target of $137.27, a modest shift from $135.53 that reflects updated assumptions in the latest analyst models. This adjustment sits against a mixed backdrop of Street commentary, with the EMANATE readout prompting both upward and downward target revisions as analysts balance Imcivree's commercial path with the potential of next generation MC4R agonists. The following sections explain how to interpret these cross currents and outline what...